http://rdf.ncbi.nlm.nih.gov/pubchem/patent/SG-11201810102S-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dd9a4b8f0e7921c3c8bf2a45a541ad67 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M5-14276 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M2005-14513 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M31-002 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M5-14276 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-605 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M31-002 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0004 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-605 |
| filingDate | 2017-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_11f9f7e9807e0d7a34d3a12f029d53fd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3160f692e556c1114eaae2435641ca1c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9141e5f99204a392e4a48818a52a61fe http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ffc1829ca38aa532e7454ff2a7021166 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ecdae9f8c40dd93719e8133f940ffb43 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d61b97373ebde56f32885d691cacb133 |
| publicationDate | 2018-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | SG-11201810102S-A |
| titleOfInvention | Glucagon-receptor selective polypeptides and methods of use thereof |
| abstract | INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111111111111111 111111111111111111111111111111111111111111111111 00 111110 1111 0111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2017/200943 Al 23 November 2017 (23.11.2017) WIPO I PCT — (51) (21) (22) (25) Filing Language: (26) (30) (71) (72) International Patent Classification: (74) Agent: ELRIFI, Ivor R. et al.; Cooley LLP, 1299 Pennsyl- A61K 38/26 (2006.01) C07K 14/605 (2006.01) vania Avenue, NW, Suite 700, Washington, District of Co- lumbia 20004 (US). International Application Number: PCT/US2017/032714 (81) Designated States (unless otherwise indicated, for every International Filing Date: kind of national protection available): AE, AG, AL, AM, 15 May 2017 (15.05.2017) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, Publication Language: English HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, Priority Data: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, 62/337,005 16 May 2016 (16.05.2016) US PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 62/414,146 28 October 2016 (28.10.2016) US SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, 62/420,937 11 November 2016 (11.11.2016) US TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Applicant: INTARCIA THERAPEUTICS, INC. (84) Designated States (unless otherwise indicated, for every [US/US]; One Marina Park Drive, 13th Floor, Boston, kind of regional protection available): ARIPO (BW, GH, Massachusetts 02210 (US). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, Inventors: BLACKWELL, William; 6 Davis Drive, PO TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Research Triangle Park, North Carolina 27709 Box 14230, EE, ES, FL FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (US). SRIVASTAVA, Ved P.; 6 Davis Drive, PO Box MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, 14230, Research Triangle Park, North Carolina 27709 (US). TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, PAULIK, Mark A.; 6 Davis Drive, PO Box 14230, Re- KM, ML, MR, NE, SN, TD, TG). search Triangle Park, North Carolina 27709 (US). YOUNG, Andrew; 6 Davis Drive, P.O. Box 14230, Research Trian- gle Park, North Carolina 27709 (US). — = = _ (54) Title: GLUCAGON-RECEPTOR SELECTIVE POLYPEPTIDES AND METHODS OF USE THEREOF FIGURE 1A human SCGR X2000 c In ri GLP-1 (7-$7) co co V Glucagon TE a 0 Compound A2 • SP-2000 =A D Compound Al u fl -4000 r tr 1.-- = = = = = = = _ _ = = = _ = = - 1-1 en 71- 01 S . > (57) 411P. thereof. ei IN , 1 of ei ---- properties © combination < -6000 -16 -14 -12 AO -8 Log [peptide] M : This invention relates to isolated polypeptides that are glucagon-receptor selective analogs and peptide derivatives These analogs are selective for human glucagon receptor with improved solubility, thermal stability, and physicochemical as compared to native endogenous glucagon. This invention also relates to methods of using such polypeptides in a variety therapeutic and diagnostic indications, as well as methods of producing such polypeptides. These analogs are useful, alone or in with other therapeutic peptides, in methods of treating obesity, diabetes, metabolic disorders, and other disorders or disease. C [Continued on next page] WO 2017/200943 Al MIDEDIMOHNIIMMEMODIMINIEHIMOVOIS Declarations under Rule 4.17: — as to applicant's entitlement to apply patent (Rule 4.17(11)) for and be granted a Published: — with international search report (Art. 21(3)) |
| priorityDate | 2016-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 71.